PSORAS
MCID: PSR001
MIFTS: 67

Psoriatic Arthritis (PSORAS)

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriatic Arthritis

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 57 12 76 25 75 43 15
Psoriatic Arthritis, Susceptibility to 57 29 13 6
Psoriatic Arthropathy 12 25 75
Arthropathic Psoriasis 12 25
Arthritis, Psoriatic 44 73
Arthritis, Psoriatic, Susceptibility to 40
Psoriasis Arthropathica 75
Arthritis Psoriatica 12
Arthritic Psoriasis 75
Arthritis Psoriatic 55
Psoras 75

Classifications:



External Ids:

OMIM 57 607507
Disease Ontology 12 DOID:9008
ICD10 33 L40.5 L40.50
ICD9CM 35 696.0
MeSH 44 D015535
NCIt 50 C61277
SNOMED-CT 68 33339001
UMLS 73 C0003872

Summaries for Psoriatic Arthritis

MedlinePlus : 43 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Etanercept and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

Genetics Home Reference : 25 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.

OMIM : 57 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507)

UniProtKB/Swiss-Prot : 75 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia : 76 Arthritis is a term often used to mean any disorder that affects joints.Symptoms generally include joint... more...

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 357)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.4 CRP HLA-B MMP3 NOD2 TNF TNFRSF11B
2 arthritis 32.8 IL1B LTA MICA MMP3 NOD2 PTPN22
3 psoriasis 32.3 HLA-C IL13 IL1B LTA MICA MIR146A
4 spondylitis 31.2 CRP HLA-B HLA-C LTA MICA NOD2
5 osteoarthritis 30.9 COMP IL1B MMP3 TNF
6 uveitis 30.8 HLA-B NOD2 TNF
7 spondyloarthropathy 30.6 HLA-B HLA-C MMP3 TNF TNFSF11
8 reactive arthritis 30.6 COMP CRP HLA-B TNF
9 skin disease 30.5 HLA-B HLA-C IL13 SELE TNF
10 juvenile rheumatoid arthritis 30.5 CRP IL1B LTA TNF TNFRSF1B
11 pneumonia 30.4 CRP IL13 IL1B TNF
12 rheumatic disease 30.4 CRP HLA-B IL1B TNF TNFRSF11B
13 temporal arteritis 30.4 CRP PTPN22 TNF
14 osteoporosis 30.4 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
15 vasculitis 30.4 CRP HLA-B SELE TNF TNFRSF1B
16 meningitis 30.3 CRP IL1B TNF
17 synovitis 30.3 COMP CRP IL1B MMP3 SELE TNF
18 cholangitis 30.3 CRP HLA-B TNF
19 diabetes mellitus 30.3 CRP HLA-B IL1B LTA PTPN22 TNF
20 tenosynovitis 30.2 COMP CRP TNFRSF1B
21 ulcerative colitis 30.2 CRP IL1B NOD2 TNF
22 joint disorders 30.2 IL1B MMP3 TNF TNFSF11
23 arteries, anomalies of 30.2 CRP IL1B SELE TNF
24 arthropathy 30.2 COMP CRP MICA TNF TNFRSF11B TNFSF11
25 alopecia areata 30.2 IL1B PTPN22 TNF
26 rheumatoid arthritis 30.2 COMP CRP HLA-B IL1B MIR146A MMP3
27 anterior uveitis 30.1 HLA-B PTPN22 TNF
28 complex regional pain syndrome 30.1 HLA-B IL1B TNF
29 tonsillitis 30.1 IL1B LTA TNF
30 atherosclerosis susceptibility 30.1 CRP SELE TNF
31 sclerosing cholangitis 30.1 HLA-B HLA-C TNF
32 melkersson-rosenthal syndrome 30.1 NOD2 TNF TNFRSF1B
33 autoimmune disease 30.1 HLA-B IL1B LTA PTPN22 TNF TNFRSF1B
34 aseptic meningitis 30.1 CD58 IL1B TNF
35 lyme disease 30.1 CRP IL1B TNF
36 periodontitis, chronic 30.0 IL1B TNFRSF11B TNFSF11
37 bronchiolitis 30.0 CRP IL13 TNF
38 periodontitis 30.0 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
39 multicentric reticulohistiocytosis 29.9 TNFRSF11B TNFSF11
40 bone disease 29.9 IL1B TNF TNFRSF11B TNFSF11
41 spondylarthropathy 29.9 LTA NOD2 TNF TNFRSF1A
42 adult-onset still's disease 29.8 CRP IL1B TNF TNFRSF1A
43 pericarditis 29.8 CRP IL1B TNF TNFRSF1A
44 periodontal disease 29.8 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
45 familial mediterranean fever 29.7 CRP IL1B NOD2 TNF TNFRSF1A
46 systemic lupus erythematosus 29.7 CRP IL1B LTA PTPN22 SELE TNF
47 demyelinating disease 29.7 IL1B TNF TNFRSF1A
48 myocardial infarction 29.5 CRP IL1B LTA MMP3 TNF
49 behcet syndrome 29.2 CRP HLA-B HLA-C IL1B LTA MICA
50 inflammatory bowel disease 29.0 CRP HLA-B IL13 IL1B LTA MMP3

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.28 HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.28 MICA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.28 HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.28 HLA-B HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.28 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.28 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.28 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.28 SELE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.28 HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.28 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.28 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.28 NOD2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.28 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.28 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.28 HLA-B HLA-C MICA NOD2 SELE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.28 NOD2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.28 NOD2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.28 HLA-C
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.28 NOD2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.28 HLA-B HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.28 NOD2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.28 SELE
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.28 NOD2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.28 MICA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.28 HLA-C
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.28 MICA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.28 HLA-B HLA-C
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.28 HLA-B HLA-C
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.28 MICA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.28 HLA-C
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL1B LTA NOD2 TNF TNFRSF11B TNFRSF1A
32 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL1B LTA NOD2 TNF TNFRSF11B TNFRSF1A

MGI Mouse Phenotypes related to Psoriatic Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 COMP IL13 IL1B LTA NOD2 PTPN22
2 cardiovascular system MP:0005385 10.22 COMP CRP IL1B LTA PTPN22 SELE
3 hematopoietic system MP:0005397 10.22 IL13 IL1B LTA MMP3 NOD2 PTPN22
4 homeostasis/metabolism MP:0005376 10.21 COMP CRP IL13 IL1B LTA MMP3
5 immune system MP:0005387 10.2 COMP CRP IL13 IL1B LTA MMP3
6 digestive/alimentary MP:0005381 10 IL13 NOD2 PTPN22 TNF TNFRSF1A TNFRSF1B
7 integument MP:0010771 9.86 IL13 IL1B SELE TNF TNFRSF1A TNFRSF1B
8 liver/biliary system MP:0005370 9.7 LTA PTPN22 SELE TNF TNFRSF1A TNFRSF1B
9 respiratory system MP:0005388 9.56 IL13 LTA PTPN22 SELE TNF TNFRSF1A
10 skeleton MP:0005390 9.36 COMP IL13 IL1B LTA MMP3 NOD2

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
2
Adalimumab Approved Phase 4,Phase 3,Phase 2,Not Applicable 331731-18-1 16219006
3
Certolizumab pegol Approved Phase 4,Phase 3,Phase 1 428863-50-7
4
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
5
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
7 Ixekizumab Approved, Investigational Phase 4,Phase 3,Phase 2 1143503-69-8
8
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10 tannic acid Approved Phase 4,Phase 3,Phase 2
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
14 beta-endorphin Phase 4
15 Melanocyte-Stimulating Hormones Phase 4
16 Hormone Antagonists Phase 4,Phase 2,Phase 1
17 Adrenocorticotropic Hormone Phase 4
18 Hormones Phase 4,Phase 2,Phase 1
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vaccines Phase 4,Phase 3,Phase 2
33 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
44 Calcineurin Inhibitors Phase 4
45 Antifungal Agents Phase 4
46 Cyclosporins Phase 4
47
Tofacitinib Approved, Investigational Phase 3 477600-75-2
48
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
49
Ustekinumab Approved, Investigational Phase 3,Phase 2 815610-63-0
50
Entecavir Approved, Investigational Phase 3 142217-69-4 153941

Interventional clinical trials:

(show top 50) (show all 348)
# Name Status NCT ID Phase Drugs
1 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
4 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
5 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) Recruiting NCT02814175 Phase 4 methotrexate (MTX)
6 A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis Not yet recruiting NCT03783026 Phase 4 CC-10004
7 Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial Not yet recruiting NCT03739853 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Adalimumab
8 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4 etanercept
9 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
10 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Recruiting NCT03419650 Phase 4 ACTHar
11 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4 Etanercept
12 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Active, not recruiting NCT03151551 Phase 4 Ixekizumab;Adalimumab
13 Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
14 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
15 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Active, not recruiting NCT02798211 Phase 4 Secukinumab;Secukinumab
16 Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. Recruiting NCT03747939 Phase 4 Apremilast (CC-10004)
17 A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Not yet recruiting NCT03733925 Phase 4 Golimumab
18 PsA Secukinumab XCT Structural Progression Study Not yet recruiting NCT03623867 Phase 4 Secukinumab;Placebo
19 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
20 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
21 Psoriatic Oligoarthritis Intervention With Symptomatic thErapy Not yet recruiting NCT03797872 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Methylprednisolone;Triamcinolone
22 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
23 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
24 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
25 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Not yet recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
26 Vascular Inflammation in Psoriasis - Apremilast Recruiting NCT03082729 Phase 4 Apremilast
27 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
28 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
29 Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence Completed NCT01079988 Phase 4 Cyclosporins;Retinoids;Systemic corticosteroids;Methotrexate;Systemic corticosteroids/methotrexate
30 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
31 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
32 Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis Recruiting NCT03486457 Phase 3 Tofacitinib;Tofacitinib
33 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis Completed NCT02024646 Phase 3 210 mg brodalumab;140 mg brodalumab;Placebo
34 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Completed NCT01892436 Phase 3 Secukinumab;Placebo
35 TIght COntrol of Psoriatic Arthritis Completed NCT01106079 Phase 3 Intensive management or Tight control;Standard management - Control group
36 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Completed NCT01925768 Phase 3 Apremilast 30 mg;Placebo
37 Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients Completed NCT02065713 Phase 3 Golimumab;Methotrexate;Placebo
38 Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis Active, not recruiting NCT02404350 Phase 3
39 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Not yet recruiting NCT03671148 Phase 3
40 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Not yet recruiting NCT03675308 Phase 3
41 Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis Terminated NCT02029495 Phase 3 210 mg brodalumab;140 mg brodalumab;Placebo
42 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed NCT01877668 Phase 3 Tofacitinib 5 mg BID;Tofacitinib 10 mg BID;Adalimumab;Placebo;Placebo
43 Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis Recruiting NCT03736161 Phase 3 Group A- Tofacitinib;Group B- Methotrexate
44 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed NCT01882439 Phase 3 Tofacitinib;Tofacitinib;Tofacitinib;Tofacitinib
45 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis Recruiting NCT02745080 Phase 3
46 Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis Recruiting NCT03598751 Phase 3 BCD-085;Placebo
47 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) Completed NCT01307423 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo
48 Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) Completed NCT00235885 Phase 3 adalimumab
49 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Completed NCT01392326 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo Comparator
50 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01172938 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 29 LTA NOD2

Anatomical Context for Psoriatic Arthritis

MalaCards organs/tissues related to Psoriatic Arthritis:

41
Skin, Bone, Testes, T Cells, Liver, Endothelial, Lung

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 1958)
# Title Authors Year
1
Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission. ( 30380114 )
2019
2
"STATus of STAT3 in Psoriatic Arthritis." ( 29439293 )
2018
3
Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study. ( 29409133 )
2018
4
Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis. ( 29452303 )
2018
5
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. ( 29441473 )
2018
6
Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database. ( 29952704 )
2018
7
Enthesitis: A hallmark of psoriatic arthritis. ( 29429762 )
2018
8
Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis. ( 29445986 )
2018
9
Lipoma Arborescens Associated With Psoriatic Arthritis in an Adolescent Boy: A Case Report and Review of the Literature. ( 29933323 )
2018
10
Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. ( 29862046 )
2018
11
Psoriatic arthritis screening by the dermatologist: development and first validation of the "PURE-4 scale". ( 29430720 )
2018
12
Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. ( 29417210 )
2018
13
Usefulness of dual-energy computed tomography for the evaluation of psoriatic arthritis accompanied by knee osteoarthritis. ( 29974970 )
2018
14
Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting. ( 29952225 )
2018
15
Early psoriatic arthritis in psoriatic patients: risk factors and screening for rheumatological evaluation. ( 29974947 )
2018
16
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naA^ve patients with active psoriatic arthritis (SPIRIT-P1). ( 29945203 )
2018
17
Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. ( 29961685 )
2018
18
Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. ( 29929736 )
2018
19
Spondyloarthritis: Which composite measures to use in psoriatic arthritis? ( 29416138 )
2018
20
Cause-specific mortality in patients with psoriasis and psoriatic arthritis. ( 29947129 )
2018
21
Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. ( 29980935 )
2018
22
'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. ( 29511028 )
2018
23
Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. ( 29398124 )
2018
24
Correction:<i>Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force</i>. ( 29440019 )
2018
25
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). ( 29411182 )
2018
26
Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis. ( 29449498 )
2018
27
Current treatment options for psoriatic arthritis: spotlight on abatacept. ( 29922065 )
2018
28
Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. ( 29449495 )
2018
29
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
2018
30
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. ( 29425183 )
2018
31
Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. ( 29948352 )
2018
32
Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. ( 29394408 )
2018
33
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. ( 29927479 )
2018
34
Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. ( 29439292 )
2018
35
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ( 29961691 )
2018
36
Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis: How Far Are We from the Truth? ( 29419446 )
2018
37
Hyperuricemia in Asian psoriatic arthritis patients. ( 29349920 )
2018
38
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. ( 29907666 )
2018
39
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. ( 29928910 )
2018
40
Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study. ( 29975012 )
2018
41
Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. ( 29949399 )
2018
42
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. ( 30522501 )
2018
43
Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology. ( 30522944 )
2018
44
Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice. ( 30526155 )
2018
45
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. ( 30526678 )
2018
46
Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis. ( 30527433 )
2018
47
Concurrent development of psoriatic arthritis, drug-induced interstitial pneumonia, and increased anti-nuclear antibodies in a patient with psoriasis vulgaris undergoing adalimumab treatment. ( 30530442 )
2018
48
Delayed Diagnosis of Psoriatic Arthritis Mutilans due to Arthritis Prior to Skin Lesion. ( 30533239 )
2018
49
To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects? ( 30535654 )
2018
50
Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS). ( 30535825 )
2018

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF TNF, -308G-A single nucleotide variant risk factor
2 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh37 Chromosome 6, 31540313: 31540313
3 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh38 Chromosome 6, 31572536: 31572536

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 CD58 CRP HLA-B HLA-C IL13 IL1B
2
Show member pathways
13.4 IL13 IL1B LTA TNF TNFRSF1A TNFRSF1B
3
Show member pathways
13.3 IL13 IL1B LTA PTPN22 TNF TNFRSF1A
4
Show member pathways
13.05 HLA-B HLA-C IL1B MICA TNF TNFRSF1A
5
Show member pathways
12.96 LTA SELE TNF TNFRSF11B TNFRSF1A TNFRSF1B
6
Show member pathways
12.92 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
7
Show member pathways
12.84 HLA-B HLA-C IL13 IL1B LTA MMP3
8
Show member pathways
12.8 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
9
Show member pathways
12.77 HLA-B HLA-C IL13 IL1B LTA TNF
10
Show member pathways
12.71 HLA-B HLA-C IL13 IL1B LTA MICA
11
Show member pathways
12.7 IL1B LTA TNF TNFRSF1A TNFRSF1B
12
Show member pathways
12.68 IL1B LTA TNF TNFRSF1A TNFRSF1B
13
Show member pathways
12.54 IL1B LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
14 12.52 IL1B PTPN22 TNF TNFRSF1A TNFRSF1B TNFSF11
15 12.44 HLA-B HLA-C LTA TNF TNFRSF1A
16
Show member pathways
12.33 IL13 IL1B MMP3 TNF
17 12.29 CD58 HLA-B HLA-C TNF
18
Show member pathways
12.26 HLA-B HLA-C IL13 IL1B LTA TNF
19 12.24 TNF TNFRSF1A TNFRSF1B TNFSF11
20 12.23 IL1B NOD2 TNF TNFRSF1A
21 12.13 CD58 HLA-B HLA-C SELE
22 12.11 IL1B SELE TNF TNFRSF1A
23
Show member pathways
12.06 IL13 IL1B MMP3 TNF
24 12.02 IL1B TNF TNFRSF11B TNFRSF1A TNFSF11
25 11.95 IL13 IL1B MMP3 TNF TNFRSF1B
26 11.88 IL1B SELE TNF
27 11.87 IL1B MMP3 TNF TNFSF11
28 11.85 IL1B LTA TNF TNFRSF1A TNFSF11
29 11.81 IL13 IL1B LTA TNF
30
Show member pathways
11.76 TNF TNFRSF1A TNFRSF1B TNFSF11
31 11.74 IL13 IL1B MMP3 TNF
32 11.71 TNF TNFRSF1A TNFRSF1B
33 11.67 IL13 IL1B TNF
34
Show member pathways
11.63 IL1B MMP3 SELE TNF TNFRSF1A
35 11.6 LTA TNF TNFRSF1A TNFRSF1B
36
Show member pathways
11.56 LTA TNF TNFRSF1A TNFRSF1B
37 11.54 COMP IL1B SELE TNF
38
Show member pathways
11.48 IL1B TNF TNFRSF11B
39 11.48 IL1B TNF TNFRSF11B TNFSF11
40 11.46 IL13 IL1B TNF TNFRSF1A TNFRSF1B
41 11.38 IL1B SELE TNF
42 11.33 TNF TNFRSF1A TNFRSF1B
43 11.33 IL13 IL1B TNF
44 11.28 IL13 IL1B TNF
45 11.27 IL1B LTA MMP3 NOD2 SELE TNF
46 11.22 IL13 IL1B LTA TNF TNFSF11
47 11.15 NOD2 TNF TNFRSF1A
48 11.03 LTA TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
49 11 IL13 IL1B LTA TNF TNFSF11
50 10.85 TNFRSF11B TNFSF11

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 CD58 HLA-B MICA SELE TNF TNFRSF1A
2 extracellular region GO:0005576 9.9 COMP CRP IL13 IL1B LTA MMP3
3 membrane raft GO:0045121 9.62 SELE TNF TNFRSF1A TNFRSF1B
4 secretory granule membrane GO:0030667 9.61 CD58 HLA-B HLA-C
5 cell surface GO:0009986 9.5 CD58 HLA-B HLA-C MICA NOD2 TNF
6 extracellular space GO:0005615 9.44 COMP CRP IL13 IL1B LTA MICA
7 MHC class I protein complex GO:0042612 9.37 HLA-B HLA-C
8 tumor necrosis factor receptor superfamily complex GO:0002947 9.26 TNFRSF1A TNFRSF1B

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.97 CD58 IL1B SELE TNF
2 cellular response to lipopolysaccharide GO:0071222 9.95 IL1B NOD2 TNF TNFRSF1B
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 IL1B NOD2 TNF TNFSF11
4 positive regulation of gene expression GO:0010628 9.91 CRP IL13 IL1B MIR146A PTPN22 TNF
5 defense response GO:0006952 9.9 NOD2 TNF TNFRSF1A TNIP1
6 defense response to Gram-positive bacterium GO:0050830 9.89 CRP LTA TNF
7 response to nutrient GO:0007584 9.88 LTA NOD2 TNFRSF11B
8 cellular response to mechanical stimulus GO:0071260 9.88 IL13 IL1B TNFRSF1A
9 positive regulation of inflammatory response GO:0050729 9.87 TNF TNFRSF1A TNIP1
10 cellular response to organic cyclic compound GO:0071407 9.86 IL1B NOD2 TNF
11 positive regulation of MAP kinase activity GO:0043406 9.85 NOD2 TNF TNFSF11
12 positive regulation of interleukin-6 production GO:0032755 9.85 IL1B NOD2 TNF
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 IL1B NOD2 TNF
14 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.83 TNF TNFRSF1A TNFRSF1B
15 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.83 IL1B NOD2 TNF TNFRSF1A TNFSF11
16 positive regulation of interferon-gamma production GO:0032729 9.81 IL1B LTA TNF
17 positive regulation of JNK cascade GO:0046330 9.81 IL1B NOD2 TNF TNFSF11
18 response to lipopolysaccharide GO:0032496 9.8 IL13 IL1B LTA PTPN22 SELE TNFRSF1B
19 cytokine-mediated signaling pathway GO:0019221 9.8 IL13 IL1B MMP3 TNF TNFRSF1A TNFRSF1B
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 IL1B PTPN22 TNF
21 regulation of inflammatory response GO:0050727 9.76 NOD2 SELE TNF TNIP1
22 inflammatory response GO:0006954 9.76 CRP IL13 IL1B SELE TNF TNFRSF1A
23 positive regulation of interleukin-8 production GO:0032757 9.72 IL1B NOD2 TNF
24 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.7 HLA-B HLA-C
25 cellular response to muramyl dipeptide GO:0071225 9.69 NOD2 PTPN22
26 negative regulation of lipid storage GO:0010888 9.69 CRP TNF
27 positive regulation of ceramide biosynthetic process GO:2000304 9.69 TNF TNFRSF1A
28 death-inducing signaling complex assembly GO:0071550 9.68 TNF TNFRSF1A
29 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
30 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.67 HLA-B HLA-C
31 positive regulation of glial cell proliferation GO:0060252 9.67 IL1B LTA TNF
32 positive regulation of neuroinflammatory response GO:0150078 9.66 IL1B TNF
33 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IL1B TNF TNFRSF1B
34 positive regulation of fever generation GO:0031622 9.64 IL1B TNF
35 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.64 LTA TNF
36 aortic valve development GO:0003176 9.62 TNFRSF1A TNFRSF1B
37 chronic inflammatory response to antigenic stimulus GO:0002439 9.62 IL1B TNF
38 negative regulation of extracellular matrix constituent secretion GO:0003332 9.61 TNFRSF1A TNFRSF1B
39 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
40 immune response GO:0006955 9.61 HLA-B HLA-C IL13 IL1B LTA MICA
41 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.58 TNFRSF1A TNFRSF1B
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
43 regulation of establishment of endothelial barrier GO:1903140 9.58 IL1B TNF TNFRSF1A
44 positive regulation of protein K63-linked ubiquitination GO:1902523 9.57 NOD2 PTPN22
45 pulmonary valve development GO:0003177 9.56 TNFRSF1A TNFRSF1B
46 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.54 LTA TNF
47 tumor necrosis factor-mediated signaling pathway GO:0033209 9.1 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
48 apoptotic process GO:0006915 10.14 COMP IL1B LTA TNFRSF11B TNFRSF1A TNFRSF1B
49 defense response to bacterium GO:0042742 10.01 MICA NOD2 TNF TNFRSF1A
50 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 IL1B NOD2 PTPN22 TNF

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CD58 COMP CRP HLA-B HLA-C IL13
2 tumor necrosis factor receptor binding GO:0005164 9.33 LTA TNF TNFSF11
3 tumor necrosis factor-activated receptor activity GO:0005031 9.32 TNFRSF1A TNFRSF1B
4 tumor necrosis factor binding GO:0043120 9.26 TNFRSF1A TNFRSF1B
5 cytokine activity GO:0005125 9.1 IL13 IL1B LTA TNF TNFRSF11B TNFSF11

Sources for Psoriatic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....